Mankind Pharma s IPO fails to attract enough retail investors, with the retail quota 8% unsubscribed. The company plans to raise ?4,326 crore through the IPO.
A majority of the brokerage firms are positive on the issue and suggest investors subscribe to the issue on a long-term basis but some analysts have raised red flags over rich valuations and the complete OFS nature.
Mankind IPO will be entirely offer for sale and its proposed equity shares will list on BSE and NSE. The pharma major expects the listing of its equity shares to enhance its visibility and brand, while also providing liquidity to its existing shareholders.